Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00004825
Other study ID # 199/13283
Secondary ID CHP-FDR001181-ST
Status Completed
Phase N/A
First received February 24, 2000
Last updated March 24, 2015
Start date May 1998
Est. completion date May 1998

Study information

Verified date July 1998
Source FDA Office of Orphan Products Development
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism.

II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population.

III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.


Description:

PROTOCOL OUTLINE: Octreotide and/or diazoxide are discontinued on day 1, and fasting blood glucose is monitored. Patients receive test meals of Sustacal on days 3 and 4 and are assessed for insulin response.

Beginning on day 5, patients are given recombinant human insulin-like growth factor I subcutaneously every 12 hours for a total of 3 doses. The first dose (on day 5) is given 30 minutes before a Sustacal challenge, the second dose is followed by a bedtime snack, and the third dose (on day 6) is followed by a supervised fast.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date May 1998
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 1 Month to 18 Years
Eligibility PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of hyperinsulinism (i.e. evidence of fasting hypoglycemia with inadequate suppression of insulin, normal pituitary and adrenal function, and increased insulin action)

Suboptimal control of blood sugar (i.e. inability to fast at least 10 hours with a blood sugar of 60 mg/dL or greater)

No suspected insulinoma

Must be currently managed on a regimen of diazoxide, octreotide and/or frequent feedings to control hypoglycemia

--Prior/Concurrent Therapy--

See Disease Characteristics

--Patient Characteristics--

Hematopoietic: No anemia or other concerns of blood volume depletion

Renal: No renal dysfunction

Other:

- No known malignancy

- No other major medical conditions

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
recombinant human insulin-like growth factor I


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
FDA Office of Orphan Products Development Children's Hospital of Philadelphia
See also
  Status Clinical Trial Phase
Completed NCT00074451 - Genomewide Search for Loci Underlying Metabolic Syndrome
Completed NCT00073775 - Epidemiology of Stress and the Metabolic Syndrome N/A
Completed NCT00005380 - Insulin, Androgen, and Risk in African-American Women N/A
Completed NCT00005709 - Lipoprotein Metabolism in Hypertensive African-Americans N/A
Recruiting NCT05088798 - Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism Phase 2
Not yet recruiting NCT05950282 - Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis
Completed NCT02248272 - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes N/A
Completed NCT00937079 - Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients Phase 1
Completed NCT00151684 - Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men Phase 2
Completed NCT00005530 - Diet, Insulin Resistance, and Cardiovascular Risk N/A
Recruiting NCT05662189 - Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus N/A
Recruiting NCT04744896 - Effects Of Combined Cryolipolysis And High Intensity Interval Training On Insulin Resistance And Body Composition In Polycystic Ovarian Patients N/A
Completed NCT05329337 - Link Between the Peripheral Mononuclear Cells' Capacity to Induce Insulin Resistance and Hyperinsulinemia N/A
Not yet recruiting NCT05989347 - Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy Phase 1
Recruiting NCT05543083 - Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes N/A
Recruiting NCT05774613 - Effect of Hibiscus Sabdariffa Beverage N/A
Recruiting NCT06363929 - Continuous Glucose Monitoring in Neonatal Hyperinsulinism
Completed NCT03358745 - Impact of Meal Order on Postprandial Cardiometabolic Risk Markers N/A
Not yet recruiting NCT05764200 - Acute Microbial Switch N/A
Completed NCT00005654 - Randomized Study of the Effect of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Obese Women With Polycystic Ovary Syndrome N/A